NEJM:BNT162b2, mRNA-1273和 Ad26.COV2.S疫苗真实世界研究结果喜人

2021-10-19 MedSci原创 MedSci原创

BNT162b2, mRNA-1273和 Ad26.COV2.S这3款疫苗表现出良好的新冠肺炎预防效果,可有效降低新冠肺炎住院、ICU治疗以及急诊入院风险

目前,FDA总计批准了3款新冠肺炎疫苗,分别为BNT162b2 (辉瑞-BioNTech), mRNA-1273 (Moderna)和 Ad26.COV2.S (强生)。在III期临床研究中,与安慰剂相比,这3款疫苗表现出良好的新冠肺炎预防效果,但缺少疫苗对新冠肺炎高危人群,如老年人、慢性疾病患者和黑人或西班牙裔人群的研究数据。近日研究人员开展真实世界研究,考察了新冠肺炎疫苗在预防新冠肺炎住院、重症监护病房(ICU)入院或急诊方面的有效性。

本次研究的参与者为50岁以上,有疑似covid-19症状的患者,患者接受了严重急性呼吸系统综合征冠状病毒2(sars-cov-2)检测。参与者于2021年1月1日至6月22日期间就诊,其中包含41552例门诊病例以及21522次急诊就诊,通过电子健康记录和免疫接种登记数据获得患者疫苗接种情况数据,主要终点为疫苗有效性。

研究发现,BNT162b2与mRNA-1273具有相近的有效性,在完成第二剂疫苗接种后14天,对实验室确认的新冠肺炎住院的预防效果为89%,ICU治疗预防效果为90%,因新冠肺炎感染导致的急诊预防效果为91%。对85岁以上老年人,患有慢性病以及黑人或西班牙裔人群,疫苗的预防效果在81-95%之间。Ad26.COV2.S疫苗对实验室确认的新冠肺炎住院的预防效果为68%,因新冠肺炎感染导致的急诊预防效果为73%

疫苗临床效果

真实世界研究中,BNT162b2, mRNA-1273和 Ad26.COV2.S这3款疫苗表现出良好的新冠肺炎预防效果,可有效降低新冠肺炎住院、ICU治疗以及急诊入院风险

原始出处:

Mark G. Thompson et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med,October 7,2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1739600, encodeId=9bc81e3960078, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jan 13 20:26:42 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822613, encodeId=c6f5182261346, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Mon Aug 08 14:26:42 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295343, encodeId=7765129534399, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Oct 20 10:26:42 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249604, encodeId=c13a12496048d, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Mon Oct 18 22:26:42 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1739600, encodeId=9bc81e3960078, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jan 13 20:26:42 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822613, encodeId=c6f5182261346, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Mon Aug 08 14:26:42 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295343, encodeId=7765129534399, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Oct 20 10:26:42 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249604, encodeId=c13a12496048d, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Mon Oct 18 22:26:42 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1739600, encodeId=9bc81e3960078, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jan 13 20:26:42 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822613, encodeId=c6f5182261346, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Mon Aug 08 14:26:42 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295343, encodeId=7765129534399, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Oct 20 10:26:42 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249604, encodeId=c13a12496048d, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Mon Oct 18 22:26:42 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1739600, encodeId=9bc81e3960078, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jan 13 20:26:42 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822613, encodeId=c6f5182261346, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Mon Aug 08 14:26:42 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295343, encodeId=7765129534399, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Oct 20 10:26:42 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249604, encodeId=c13a12496048d, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Mon Oct 18 22:26:42 CST 2021, time=2021-10-18, status=1, ipAttribution=)]

相关资讯

持续远程生命体征监测是否能减少对疑似新冠肺炎患者的访视次数?

新冠肺炎流行期间持续生命体征监测对疑似COVID-19患者的就诊次数、获取生命体征的就诊次数以及个人防护设备使用数量的影响。

利用Nichi葡聚糖变体控制新冠肺炎引发的细胞因子风暴和凝血病标志物;同类首创临床研究报告

IL-6、D二聚体长期处治良好,具有可带来临床益处的免疫调节作用。

新冠发病另一种机制被找到!研发抑制透明质酸合成的特效药有望成为治疗新冠肺炎的新策略

复旦大学生物医学研究院的一个研究团队,发现了一类在细胞核内发挥独特激活作用的NamiRNA,创造性地提出NamiRNA-增强子-基因激活理论,这也为新冠致病新机制的研究打下基础。

Thorax:新冠肺炎患者的内皮生物标志物急性并持续增加

COVID-19诊断时内皮损伤程度与疾病严重程度和预后有关。

Thorax:吸烟影响新冠肺炎预后?

吸烟与新冠肺炎风险及严重程度的相关性?

JAAD:特应性皮炎患者新冠肺炎感染风险的回顾性队列研究

 在这项以人群为基础的大规模研究中,发现成年人感染新冠肺炎与AD相关的风险略有增加。与其他全身药物相比,dupilumab感染新冠肺炎的风险较低。